[{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparc Reports Positive Top-Line Results of Phase 3 Clinical Trial of SDN-037","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Viatris Announces Two Acquisitions to Create What it Expects to be a Leading Ophthalmology Franchise; Plans to Provide Strategic Update on its February 2022 Investor Event","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Famy Life Sciences"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$280.0 million","upfrontCash":"Undisclosed","newsHeadline":"Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Viatris Eye Care Division","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Famy Life Sciences"},{"orgOrder":0,"company":"Entod Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entod Pharma Gets DCGI Nod to Conduct Phase III Study of 0.05% Atropine","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Entod Pharmaceuticals"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biocon Biologics Announces Positive CHMP Opinion for YESAFILI, Biosimilar Aflibercept","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Biocon"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
YESAFILI (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat neovascular (wet) age-related macular degeneration (AMD), various types of macular edema and diabetic retinopathy.
With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.
With the combination of Viatris' global commercial footprint, R&D and regulatory capabilities, along with Famy Life Sciences' Phase III-ready pipeline, the Company believes it has the foundation to create a leading global ophthalmology franchise.
A statistically significant proportion of patients treated with SDN-037 achieved an ACC grade of 0 versus vehicle with p-values <0.0001 in the Intent-To-Treat population.